July 11, 2023
3 min watch
Save
VIDEO: Mouse trial in cabozantinib-resistant renal cell carcinoma shows promise
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Farshid Sadeghi, MD, discussed data for a study examining cabozantinib-resistant kidney cancer at American Urological Association Annual Meeting.
Sadeghi, a clinical assistant professor at City of Hope Phoenix, highlighted a South Korean study that noted high rates of mutation in cabozantinib-resistant renal cell carcinoma and looked at ways to make them responsive to cabozantinib (Cabometyx, Exelixis) in mice.
“How this correlates to humans needs a lot more investigation, but as a physician who sees patients who have progression of disease on cabozantinib, this research is promising,” Sadeghi said.
Reference:
- Park JS, et al. PD24-08. Presented at: American Urological Association Annual Meeting; April 28-May 1, 2023; Chicago.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Sadeghi reports no relevant financial disclosures.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.